Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
ConditionHypercholesterolemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFederico II University
About this trial
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
Eligibility criteria
Qualifiers
Patients under PCSK9 inhibitor treatment.
Disqualifiers
Age < 18 years o > 80 years;
Patients who refuse to participate and to sign informed consent.
Trial design
Treatments tested in this trial
- Repatha (evolocumab); Praluent (alirocumab)
Treatment groups
5,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov